Mathematical modeling of N-803 treatment in SIV-infected non-human primates

• Published in: PLoS computational biology 2021-07, Vol.17 (7), p.e1009204-e1009204
• Main Authors: Cody, Jonathan W, Ellis-Connell, Amy L, O'Connor, Shelby L, Pienaar, Elsje
• Format: Article
• Language: English
• Subjects: Biology and life sciences; CD8 antigen; Cell activation; Cell culture; Cytokines; Cytotoxicity; Dosage; Drug dosages; Drug therapy; Drug tolerance; GLP-1 receptor agonists; Health aspects; HIV; Human immunodeficiency virus; Immune system; Immunological tolerance; Immunomodulation; Immunoregulation; Immunosuppressive agents; Immunotherapy; Infections; Interleukin 15; Interleukins; Lymphocytes; Lymphocytes T; Mathematical analysis; Mathematical models; Medicine and health sciences; Methods; Natural killer cells; PD-L1 protein; Pharmacokinetics; Plasma; Population studies; Populations; Primates; Qualitative analysis; Simian immunodeficiency virus; Vaccination; Vaccines; Viral infections; Virus diseases; Viruses
• ISSN: 1553-7358; 1553-734X; 1553-7358
• DOI: 10.1371/journal.pcbi.1009204

Immunomodulatory drugs could contribute to a functional cure for Human Immunodeficiency Virus (HIV). Interleukin-15 (IL-15) promotes expansion and activation of CD8 + T cell and natural killer (NK) cell populations. In one study, an IL-15 superagonist, N-803, suppressed Simian Immunodeficiency Virus (SIV) in non-human primates (NHPs) who had received prior SIV vaccination. However, viral suppression attenuated with continued N-803 treatment, partially returning after long treatment interruption. While there is evidence of concurrent drug tolerance, immune regulation, and viral escape, the relative contributions of these mechanisms to the observed viral dynamics have not been quantified. Here, we utilize mathematical models of N-803 treatment in SIV-infected macaques to estimate contributions of these three key mechanisms to treatment outcomes: 1) drug tolerance, 2) immune regulation, and 3) viral escape. We calibrated our model to viral and lymphocyte responses from the above-mentioned NHP study. Our models track CD8 + T cell and NK cell populations with N-803-dependent proliferation and activation, as well as viral dynamics in response to these immune cell populations. We compared mathematical models with different combinations of the three key mechanisms based on Akaike Information Criterion and important qualitative features of the NHP data. Two minimal models were capable of reproducing the observed SIV response to N-803. In both models, immune regulation strongly reduced cytotoxic cell activation to enable viral rebound. Either long-term drug tolerance or viral escape (or some combination thereof) could account for changes to viral dynamics across long breaks in N-803 treatment. Theoretical explorations with the models showed that less-frequent N-803 dosing and concurrent immune regulation blockade (e.g. PD-L1 inhibition) may improve N-803 efficacy. However, N-803 may need to be combined with other immune therapies to countermand viral escape from the CD8 + T cell response. Our mechanistic model will inform such therapy design and guide future studies.